Breakthrough Alzheimer's Drug Shows Promise in Slowing Cognitive Decline

A new drug called donanemab has shown promising results in a major clinical trial, significantly slowing down cognitive decline in patients with early-stage Alzheimer's disease. While not a cure, the drug could potentially allow individuals suffering from the disease to live longer and less-impeded lives. The treatment, produced by pharmaceutical company Eli Lilly, reduced cognitive decline by approximately 35 percent. However, there are risks associated with the drug, including serious side effects such as brain swelling. Despite this, experts are hailing donanemab as a turning point in the fight against Alzheimer's, offering hope for future treatments that could effectively manage symptoms and improve the quality of life for patients.